VS 4718

Drug Profile

VS 4718

Alternative Names: VS-4718

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator The Scripps Research Institute
  • Developer Verastem
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Jun 2017 Verastem terminates a phase I trial in Solid tumours (Metastatic disease, Late-stage disease) in USA due to sponsor's decision to deprioritise the program(NCT01849744)
  • 23 Mar 2017 Discontinued - Phase-I for Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in USA (PO)
  • 23 Mar 2017 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top